{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:24:13Z","timestamp":1793687053591,"version":"4.5.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Brincidofovir (BCV) and tecovirimat are the only two chemical drugs that have been approved to treat smallpox and can be requested for monkeypox (Mpox) treatment through a single-patient Emergency Investigational New Drug (EIND) application. Disappointedly, the efficacy of tecovirimat manifested in recent clinical trials is far from being satisfactory, while the clinical efficacy of BCV is still inconclusive. Given that monkeypox virus (MPXV), variola and other emerging orthopoxviruses are posing serious threats to global health, it is urgent to develop better therapeutics. In this study, we tested the antiviral effects of three novel prodrugs, which were designed based on previously reported parent drugs, either (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine ((S)-HPMPC, cidofovir) or (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine ((S)-HPMPA). We found that one of the (S)-HPMPA-based prodrugs, ODE-(S)-HPMPA formate, exhibited significantly better anti-orthopoxvirus activity than BCV both in vitro and in vivo, which also inhibited human adenovirus type 2 and type 21 more efficiently than BCV. Most strikingly, the EC\n                    <jats:sub>50<\/jats:sub>\n                    and EC\n                    <jats:sub>90<\/jats:sub>\n                    of ODE-(S)-HPMPA formate against MPXV were more than 40-fold lower than those of BCV. In contrast, we observed that the anti-herpes simplex virus type 1 (HSV-1) activities of the (S)-HPMPA-based prodrugs were less effective than those of the cidofovir-based prodrugs (BCV and BCV formate), especially in vivo. Moreover, we showed for the first time that cytidine and adenine analog combined therapies could provide mice with complete protection against lethal challenges of both vaccinia and HSV-1. Collectively, we propose that both the ODE-(S)-HPMPA formate and the BCV\/ODE-(S)-HPMPA formate combination are worth further investigations for their potential clinical applications.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02207-w","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T19:02:26Z","timestamp":1744311746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Novel derivatives of brincidofovir and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine inhibit orthopoxviruses and human adenoviruses more potently than brincidofovir"],"prefix":"10.1038","volume":"10","author":[{"given":"Yifan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-9423","authenticated-orcid":false,"given":"Yanmin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-5219","authenticated-orcid":false,"given":"Chao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahui","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanhai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-5141","authenticated-orcid":false,"given":"Youchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2207_CR1","doi-asserted-by":"crossref","unstructured":"Petersen, B. W., Karem, K. L. & Damon, I. K. in Viral Infections of Humans, (eds Kaslow, R., Stanberry, L., & Le Duc, J.) 501-517 (Springer, 2014).","DOI":"10.1007\/978-1-4899-7448-8_21"},{"key":"2207_CR2","doi-asserted-by":"publisher","first-page":"101487","DOI":"10.1016\/j.nmni.2024.101487","volume":"62","author":"P Singh","year":"2024","unstructured":"Singh, P. et al. The resurgence of monkeypox: epidemiology, clinical features, and public health implications in the post-smallpox eradication era. New Microbes New Infect 62, 101487 (2024).","journal-title":"New Microbes New Infect"},{"key":"2207_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0966-842X(00)01855-2","volume":"9","author":"P Berche","year":"2001","unstructured":"Berche, P. The threat of smallpox and bioterrorism. Trends Microbiol. 9, 15\u201318 (2001).","journal-title":"Trends Microbiol."},{"key":"2207_CR4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1046\/j.1469-0691.2002.00525.x","volume":"8","author":"A Tegnell","year":"2002","unstructured":"Tegnell, A., Wahren, B. & Elgh, F. Smallpox\u2013eradicated, but a growing terror threat. Clin. Microbiol. Infect. 8, 504\u2013509 (2002).","journal-title":"Clin. Microbiol. Infect."},{"key":"2207_CR5","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","volume":"184","author":"L Lu","year":"2021","unstructured":"Lu, L., Su, S., Yang, H. & Jiang, S. Antivirals with common targets against highly pathogenic viruses. Cell 184, 1604\u20131620 (2021).","journal-title":"Cell"},{"key":"2207_CR6","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.3390\/molecules27217370","volume":"27","author":"S Peng","year":"2022","unstructured":"Peng, S., Wang, H., Wang, Z. & Wang, Q. Progression of antiviral agents targeting viral polymerases. Molecules 27, 7370 (2022).","journal-title":"Molecules"},{"key":"2207_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/ph17050661","volume":"17","author":"D Palazzotti","year":"2024","unstructured":"Palazzotti, D. et al. Small molecule drugs targeting viral polymerases. Pharmaceuticals 17, 661 (2024).","journal-title":"Pharmaceuticals"},{"key":"2207_CR8","doi-asserted-by":"publisher","first-page":"105182","DOI":"10.1016\/j.antiviral.2021.105182","volume":"195","author":"K Chan-Tack","year":"2021","unstructured":"Chan-Tack, K. et al. Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration\u2019s Evaluation. Antiviral Res. 195, 105182 (2021).","journal-title":"Antiviral Res."},{"key":"2207_CR9","doi-asserted-by":"crossref","unstructured":"Magee, W. C. & Evans, D. H. The antiviral activity and mechanism of action of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] (HPMP) nucleosides .Antiviral Res. 96, 169\u2013180 (2012).","DOI":"10.1016\/j.antiviral.2012.08.010"},{"key":"2207_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2217\/fmb-2019-0288","volume":"15","author":"JJ Alvarez-Cardona","year":"2020","unstructured":"Alvarez-Cardona, J. J., Whited, L. K. & Chemaly, R. F. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections. Future Microbiol. 15, 389\u2013400 (2020).","journal-title":"Future Microbiol."},{"key":"2207_CR11","doi-asserted-by":"publisher","first-page":"e01683","DOI":"10.1128\/AAC.01683-19","volume":"64","author":"D Delaune","year":"2020","unstructured":"Delaune, D. & Iseni, F. Drug development against smallpox: present and future. Antimicrob. Agents Chemother. 64, e01683\u201319 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2207_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1056\/NEJMc2212136","volume":"388","author":"D Bojkova","year":"2023","unstructured":"Bojkova, D. et al. Drug sensitivity of currently circulating mpox viruses. N. Engl. J. Med. 388, 279\u2013281 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2207_CR13","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/s41564-022-01269-8","volume":"7","author":"G Frenois-Veyrat","year":"2022","unstructured":"Frenois-Veyrat, G. et al. Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations. Nat. Microbiol. 7, 1951\u20131955 (2022).","journal-title":"Nat. Microbiol."},{"key":"2207_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/14728222.2023.2230361","volume":"27","author":"SN Byrareddy","year":"2023","unstructured":"Byrareddy, S. N. et al. Potential therapeutic targets for Mpox: the evidence to date. Expert Opin. Ther. Targets 27, 419\u2013431 (2023).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2207_CR15","first-page":"181","volume":"13","author":"S Duraffour","year":"2010","unstructured":"Duraffour, S., Andrei, G. & Snoeck, R. Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. IDrugs 13, 181\u2013191 (2010).","journal-title":"IDrugs"},{"key":"2207_CR16","doi-asserted-by":"publisher","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","volume":"79","author":"G Yang","year":"2005","unstructured":"Yang, G. et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol. 79, 13139\u201313149 (2005).","journal-title":"J. Virol."},{"key":"2207_CR17","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1134\/S0022476624040139","volume":"65","author":"SS Borisevich","year":"2024","unstructured":"Borisevich, S. S., Gorokhov, Y. V. & Arkhipov, S. G. Binding Site of Tecovirimat, Inhibitor of the p37 Membrane Protein of Orthopox Viruses. J. Struct. Chem. 65, 776\u2013785 (2024).","journal-title":"J. Struct. Chem."},{"key":"2207_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14787210.2020.1819791","volume":"19","author":"AT Russo","year":"2021","unstructured":"Russo, A. T. et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev. Anti Infect Ther. 19, 331\u2013344 (2021).","journal-title":"Expert Rev. Anti Infect Ther."},{"key":"2207_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijid.2022.11.040","volume":"127","author":"MA Shamim","year":"2023","unstructured":"Shamim, M. A. et al. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review. Int. J. Infect. Dis. 127, 150\u2013161 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"2207_CR20","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(22)00228-6","volume":"22","author":"H Adler","year":"2022","unstructured":"Adler, H. et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect. Dis. 22, 1153\u20131162 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"2207_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40506-022-00260-5","volume":"14","author":"AH Barnes","year":"2022","unstructured":"Barnes, A. H., Smith, C., Dash, A. & Shishido, A. A. Mpox: special considerations in the immunocompromised host. Curr. Treat Options Infect. Dis. 14, 43\u201366 (2022).","journal-title":"Curr. Treat Options Infect. Dis."},{"key":"2207_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/biomedicines11020278","volume":"11","author":"M Imran","year":"2023","unstructured":"Imran, M. et al. Oral Brincidofovir therapy for monkeypox outbreak: a focused review on the therapeutic potential, clinical studies, patent literature, and prospects. Biomedicines 11, 278 (2023).","journal-title":"Biomedicines"},{"key":"2207_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa1705688","volume":"379","author":"DW Grosenbach","year":"2018","unstructured":"Grosenbach, D. W. et al. Oral Tecovirimat for the treatment of smallpox. N. Engl. J. Med. 379, 44\u201353 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2207_CR24","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/jac\/dku545","volume":"70","author":"S Duraffour","year":"2015","unstructured":"Duraffour, S. et al. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping. J. Antimicrob. Chemother. 70, 1367\u20131380 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"2207_CR25","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3201\/eid2912.231146","volume":"29","author":"TG Smith","year":"2023","unstructured":"Smith, T. G. et al. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023. Emerg. Infect. Dis. 29, 2426\u20132432 (2023).","journal-title":"Emerg. Infect. Dis."},{"key":"2207_CR26","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1056\/NEJMc2214921","volume":"388","author":"J Alarc\u00f3n","year":"2023","unstructured":"Alarc\u00f3n, J. et al. An Mpox-related death in the United States. N. Engl. J. Med. 388, 1246\u20131247 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2207_CR27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/d41586-024-02694-x","volume":"632","author":"M Lenharo","year":"2024","unstructured":"Lenharo, M. Hopes dashed for drug aimed at monkeypox virus spreading in Africa. Nature 632, 965 (2024).","journal-title":"Nature"},{"key":"2207_CR28","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.3390\/v2122803","volume":"2","author":"G Andrei","year":"2010","unstructured":"Andrei, G. & Snoeck, R. Cidofovir activity against Poxvirus Infections. Viruses 2, 2803\u20132830 (2010).","journal-title":"Viruses"},{"key":"2207_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1128\/CMR.00009-10","volume":"23","author":"NS Lurain","year":"2010","unstructured":"Lurain, N. S. & Chou, S. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23, 689\u2013712 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"2207_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1743-422X-7-110","volume":"7","author":"J Farlow","year":"2010","unstructured":"Farlow, J., Ichou, M. A., Huggins, J. & Ibrahim, S. Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus. Virol. J. 7, 110 (2010).","journal-title":"Virol. J."},{"key":"2207_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/v13010043","volume":"13","author":"NIO Silva","year":"2020","unstructured":"Silva, N. I. O., de Oliveira, J. S., Kroon, E. G., Trindade, G. S. & Drumond, B. P. Here, there, and everywhere: the wide host range and geographic distribution of Zoonotic Orthopoxviruses. Viruses 13, 43 (2020).","journal-title":"Viruses"},{"key":"2207_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jobb.2022.12.004","volume":"5","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., Zhou, Y., Pei, R., Chen, X. & Wang, Y. Potential threat of human pathogenic orthopoxviruses to public health and control strategies. J. Biosaf. Biosecur. 5, 1\u20137 (2023).","journal-title":"J. Biosaf. Biosecur."},{"key":"2207_CR33","doi-asserted-by":"publisher","first-page":"e1003756","DOI":"10.1371\/journal.ppat.1003756","volume":"9","author":"SN Shchelkunov","year":"2013","unstructured":"Shchelkunov, S. N. An increasing danger of zoonotic orthopoxvirus infections. PLoS Pathog. 9, e1003756 (2013).","journal-title":"PLoS Pathog."},{"key":"2207_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/v15010103","volume":"15","author":"GA Shchelkunova","year":"2022","unstructured":"Shchelkunova, G. A. & Shchelkunov, S. N. Smallpox, monkeypox and other human orthopoxvirus infections. Viruses 15, 103 (2022).","journal-title":"Viruses"},{"key":"2207_CR35","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd1877","volume":"4","author":"E De Clercq","year":"2005","unstructured":"De Clercq, E. & Hol\u00fd, A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4, 928\u2013940 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2207_CR36","doi-asserted-by":"publisher","first-page":"105799","DOI":"10.1016\/j.antiviral.2024.105799","volume":"222","author":"AE Tollefson","year":"2024","unstructured":"Tollefson, A. E. et al. Oral USC-093, a novel homoserinamide analogue of the tyrosinamide (S)-HPMPA prodrug USC-087 has decreased nephrotoxicity while maintaining antiviral efficacy against human adenovirus infection of Syrian hamsters. Antiviral Res. 222, 105799 (2024).","journal-title":"Antiviral Res."},{"key":"2207_CR37","doi-asserted-by":"crossref","unstructured":"Luo, M. et al. Amidate Prodrugs of Cyclic 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]adenine with Potent Anti-Herpesvirus Activity. ACS Med. Chem. Lett. 9, 381\u2013385 (2018)..","DOI":"10.1021\/acsmedchemlett.8b00079"},{"key":"2207_CR38","unstructured":"Beadle, J. R. in Current Protocols in Nucleic Acid Chemistry, (Wiley, 2007)."},{"key":"2207_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.antiviral.2008.01.155","volume":"79","author":"DC Quenelle","year":"2008","unstructured":"Quenelle, D. C. et al. Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models. Antiviral Res. 79, 133\u2013135 (2008).","journal-title":"Antiviral Res."},{"key":"2207_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.antiviral.2006.11.010","volume":"75","author":"F Dal Pozzo","year":"2007","unstructured":"Dal Pozzo, F. et al. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Res. 75, 52\u201357 (2007).","journal-title":"Antiviral Res."},{"key":"2207_CR41","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1128\/AAC.00114-09","volume":"53","author":"JD Morrey","year":"2009","unstructured":"Morrey, J. D., Korba, B. E., Beadle, J. R., Wyles, D. L. & Hostetler, K. Y. Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. Antimicrob Agents Chemother. 53, 2865\u20132870 (2009).","journal-title":"Antimicrob Agents Chemother."},{"key":"2207_CR42","doi-asserted-by":"crossref","unstructured":"Quenelle, D. C. et al. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.Antimicrob. Agents Chemother. 51, 3940\u20133947 (2007).","DOI":"10.1128\/AAC.00184-07"},{"key":"2207_CR43","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1021\/jm050473m","volume":"49","author":"JR Beadle","year":"2006","unstructured":"Beadle, J. R. et al. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J. Med. Chem. 49, 2010\u20132015 (2006).","journal-title":"J. Med. Chem."},{"key":"2207_CR44","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.bmc.2011.03.034","volume":"19","author":"J Ruiz","year":"2011","unstructured":"Ruiz, J. et al. Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine. Bioorg. Med. Chem 19, 2950\u20132958 (2011).","journal-title":"Bioorg. Med. Chem"},{"key":"2207_CR45","doi-asserted-by":"crossref","unstructured":"Hostetler, K. Y., Aldern, K. A., Wan, W. B., Ciesla, S. L. & Beadle, J. R. Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 50, 2857\u20132859 (2006).","DOI":"10.1128\/AAC.01223-05"},{"key":"2207_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.antiviral.2009.09.012","volume":"84","author":"N Valiaeva","year":"2009","unstructured":"Valiaeva, N. et al. Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses. Antiviral Res. 84, 254\u2013259 (2009).","journal-title":"Antiviral Res."},{"key":"2207_CR47","doi-asserted-by":"crossref","unstructured":"Zakharova, V. M. et al. Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. J. Med. Chem. 54, 5680\u20135693 (2011).","DOI":"10.1021\/jm2001426"},{"key":"2207_CR48","doi-asserted-by":"crossref","unstructured":"Krecmerov\u00e1, M. et al. Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. J. Med. Chem. 53, 6825\u20136837 (2010).","DOI":"10.1021\/jm901828c"},{"key":"2207_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/cid\/ciac622","volume":"76","author":"EA Siegrist","year":"2023","unstructured":"Siegrist, E. A. & Sassine, J. Antivirals with activity against mpox: a clinically oriented review. Clin. Infect. Dis. 76, 155\u2013164 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"2207_CR50","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.it.2012.07.003","volume":"33","author":"M Rincon","year":"2012","unstructured":"Rincon, M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 33, 571\u2013577 (2012).","journal-title":"Trends Immunol."},{"key":"2207_CR51","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/v11090772","volume":"11","author":"Y Guo","year":"2019","unstructured":"Guo, Y., Cao, W. & Zhu, Y. Immunoregulatory Functions of the IL-12 Family of Cytokines in antiviral systems. Viruses 11, 772 (2019).","journal-title":"Viruses"},{"key":"2207_CR52","doi-asserted-by":"publisher","first-page":"15935","DOI":"10.1073\/pnas.2004615117","volume":"117","author":"MJ Tuazon Kels","year":"2020","unstructured":"Tuazon Kels, M. J. et al. TNF deficiency dysregulates inflammatory cytokine production, leading to lung pathology and death during respiratory poxvirus infection. Proc. Natl. Acad. Sci. USA 117, 15935\u201315946 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2207_CR53","doi-asserted-by":"crossref","unstructured":"Potmesil, P., Krecmerov\u00e1, M., Kmon\u00edckov\u00e1, E., Hol\u00fd, A. & Z\u00eddek, Z. Nucleotide analogues with immunobiological properties: 9-[2-Hydroxy-3-(phosphonomethoxy)propyl]-adenine (HPMPA), -2,6-diaminopurine (HPMPDAP), and their N6-substituted derivatives. Eur. J. Pharmacol. 540, 191\u2013199 (2006).","DOI":"10.1016\/j.ejphar.2006.04.018"},{"key":"2207_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170236","volume":"133","author":"M Karim","year":"2023","unstructured":"Karim, M., Lo, C. W. & Einav, S. Preparing for the next viral threat with broad-spectrum antivirals. J. Clin. Investig. 133, e170236 (2023).","journal-title":"J. Clin. Investig."},{"key":"2207_CR55","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1038\/s41409-021-01285-y","volume":"56","author":"K Perruccio","year":"2021","unstructured":"Perruccio, K. et al. Safety and efficacy of brincidofovir for Adenovirus infection in children receiving allogeneic stem cell transplantation: an AIEOP retrospective analyses. Bone Marrow Transpl. 56, 3104\u20133107 (2021).","journal-title":"Bone Marrow Transpl."},{"key":"2207_CR56","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrd4010","volume":"12","author":"LP Jordheim","year":"2013","unstructured":"Jordheim, L. P., Durantel, D., Zoulim, F. & Dumontet, C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Discov. 12, 447\u2013464 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2207_CR57","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3390\/v11080745","volume":"11","author":"OB Peersen","year":"2019","unstructured":"Peersen, O. B. A comprehensive superposition of viral polymerase structures. Viruses 11, 745 (2019).","journal-title":"Viruses"},{"key":"2207_CR58","doi-asserted-by":"crossref","unstructured":"Modrow, S., Dietrich, F., Truyen, U. & Sch\u00e4tzl, H. in Molecular Virology (eds Modrow, S., Falke, D., Truyen, U., & Sch\u00e4tzl, H.) 625\u2013873 (Springer, 2013).","DOI":"10.1007\/978-3-642-20718-1_19"},{"key":"2207_CR59","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/infdis\/jiad034","volume":"228","author":"P Li","year":"2023","unstructured":"Li, P. et al. Clinical features, antiviral treatment, and patient outcomes: a systematic review and comparative analysis of the previous and the 2022 Mpox outbreaks. J. Infect. Dis. 228, 391\u2013401 (2023).","journal-title":"J. Infect. Dis."},{"key":"2207_CR60","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/biomedicines10030580","volume":"10","author":"G Andrei","year":"2022","unstructured":"Andrei, G. et al. Poxviruses bearing DNA polymerase mutations show complex patterns of cross-resistance. Biomedicines 10, 580 (2022).","journal-title":"Biomedicines"},{"key":"2207_CR61","doi-asserted-by":"publisher","first-page":"9391","DOI":"10.1128\/JVI.00605-06","volume":"80","author":"G Andrei","year":"2006","unstructured":"Andrei, G. et al. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 80, 9391\u20139401 (2006).","journal-title":"J. Virol."},{"key":"2207_CR62","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2471\/BLT.19.237149","volume":"98","author":"C James","year":"2020","unstructured":"James, C. et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull. World Health Organ 98, 315\u2013329 (2020).","journal-title":"Bull. World Health Organ"},{"key":"2207_CR63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0378-1119(87)90039-4","volume":"52","author":"T Tsurumi","year":"1987","unstructured":"Tsurumi, T., Maeno, K. & Nishiyama, Y. Nucleotide sequence of the DNA polymerase gene of herpes simplex virus type 2 and comparison with the type 1 counterpart. Gene 52, 129\u2013137 (1987).","journal-title":"Gene"},{"key":"2207_CR64","unstructured":"In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/ (2012)."},{"key":"2207_CR65","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.3390\/cimb45080433","volume":"45","author":"PN Kamzeeva","year":"2023","unstructured":"Kamzeeva, P. N., Aralov, A. V., Alferova, V. A. & Korshun, V. A. Recent advances in molecular mechanisms of nucleoside antivirals. Curr. Issues Mol. Biol. 45, 6851\u20136879 (2023).","journal-title":"Curr. Issues Mol. Biol."},{"key":"2207_CR66","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/biomedicines6010030","volume":"6","author":"S Khanal","year":"2018","unstructured":"Khanal, S., Ghimire, P. & Dhamoon, A. S. The repertoire of adenovirus in human disease: the innocuous to the deadly. Biomedicines 6, 30 (2018).","journal-title":"Biomedicines"},{"key":"2207_CR67","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/apa.16207","volume":"111","author":"M Dotan","year":"2022","unstructured":"Dotan, M. et al. Adenovirus can be a serious, life-threatening disease, even in previously healthy children. Acta Paediatr. 111, 614\u2013619 (2022).","journal-title":"Acta Paediatr."},{"key":"2207_CR68","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood-2016-11-749721","volume":"129","author":"P Hiwarkar","year":"2017","unstructured":"Hiwarkar, P. et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood 129, 2033\u20132037 (2017).","journal-title":"Blood"},{"key":"2207_CR69","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1016\/j.cell.2023.08.023","volume":"186","author":"M Aid","year":"2023","unstructured":"Aid, M. et al. Mpox infection protects against re-challenge in rhesus macaques. Cell 186, 4652\u20134661 (2023).","journal-title":"Cell"},{"key":"2207_CR70","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00209-23","volume":"97","author":"S Zhao","year":"2023","unstructured":"Zhao, S. et al. Generation of human embryonic stem cell-derived lung organoids for modeling infection and replication differences between human adenovirus types 3 and 55 and evaluating potential antiviral drugs. J. Virol. 97, e0020923 (2023).","journal-title":"J. Virol."},{"key":"2207_CR71","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.3441","volume":"9","author":"L Grosche","year":"2019","unstructured":"Grosche, L. et al. Herpes Simplex Virus Type 1 propagation, titration and single-step growth curves. Bio Protoc. 9, e3441 (2019).","journal-title":"Bio Protoc."},{"key":"2207_CR72","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.antiviral.2018.09.015","volume":"159","author":"CB Hartline","year":"2018","unstructured":"Hartline, C. B. et al. A standardized approach to the evaluation of antivirals against DNA viruses: Orthopox-, adeno-, and herpesviruses. Antiviral Res. 159, 104\u2013112 (2018).","journal-title":"Antiviral Res."},{"key":"2207_CR73","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1128\/AAC.05983-11","volume":"56","author":"W Painter","year":"2012","unstructured":"Painter, W. et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob. Agents Chemother. 56, 2726\u20132734 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2207_CR74","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3390\/vaccines10071147","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Immune correlates of disseminated BCG infection in IL12RB1-Deficient Mice. Vaccines 10, 1147 (2022).","journal-title":"Vaccines"}],"updated-by":[{"DOI":"10.1038\/s41392-026-02809-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000}}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02207-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02207-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02207-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:02:45Z","timestamp":1782496965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02207-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2207"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02207-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41392-026-02809-y","URL":"https:\/\/doi.org\/10.1038\/s41392-026-02809-y","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patent applications regarding the novel prodrugs evaluated in this study have been jointly filed by Shanghai Sci-Tech Inno Center for Infection & Immunity and Risen Pharma Tech Co., Ltd.. The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}